<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28388647</article-id><article-id pub-id-type="pmc">5384743</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0173802</article-id><article-id pub-id-type="publisher-id">PONE-D-16-40767</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Probiotics</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbiome</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Genomics</subject><subj-group><subject>Microbial Genomics</subject><subj-group><subject>Microbiome</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Microbial Genomics</subject><subj-group><subject>Microbiome</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Response</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Response</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Bacterial Pathogens</subject><subj-group><subject>Clostridium</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Bacterial Pathogens</subject><subj-group><subject>Clostridium</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Bacteria</subject><subj-group><subject>Gut Bacteria</subject><subj-group><subject>Clostridium</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Bacteria</subject><subj-group><subject>Gut Bacteria</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Response</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Response</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Fungi</subject><subj-group><subject>Yeast</subject><subj-group><subject>Saccharomyces</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Impact of probiotic <italic>Saccharomyces boulardii</italic> on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial</article-title><alt-title alt-title-type="running-head">Impact of probiotic <italic>Saccharomyces boulardii</italic> in gut microbiome composition in HIV-treated patients</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-2813-8426</contrib-id><name><surname>Villar-Garc&#x000ed;a</surname><given-names>Judit</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><name><surname>G&#x000fc;erri-Fern&#x000e1;ndez</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Moya</surname><given-names>Andr&#x000e9;s</given-names></name><xref ref-type="aff" rid="aff004"><sup>4</sup></xref><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gonz&#x000e1;lez</surname><given-names>Alicia</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hern&#x000e1;ndez</surname><given-names>Juan J.</given-names></name><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lerma</surname><given-names>Elisabet</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Guelar</surname><given-names>Ana</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sorli</surname><given-names>Luisa</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Horcajada</surname><given-names>Juan P.</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Artacho</surname><given-names>Alejandro</given-names></name><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>D&#x000b4;Auria</surname><given-names>Giuseppe</given-names></name><xref ref-type="aff" rid="aff004"><sup>4</sup></xref><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Knobel</surname><given-names>Hernando</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label><addr-line>Department of Infectious Diseases, Hospital del Mar, Barcelona, Spain</addr-line></aff><aff id="aff002"><label>2</label><addr-line>IMIM (Hospital del Mar Medical Research Institute, Institut Hospital del Mar d'Investigacions Mediques), Barcelona, Spain</addr-line></aff><aff id="aff003"><label>3</label><addr-line>Department of Medicine, Universitat Aut&#x000f2;noma de Barcelona, Spain</addr-line></aff><aff id="aff004"><label>4</label><addr-line>Joint Unit of Research in Genomics and Health, Foundation for the Promotion of Health and Biomedical Research in the Valencian Community (FISABIO) and Cavanilles Institute of Biodiversity and Evolutionary Biology (Universitat de Val&#x000e8;ncia), Val&#x000e8;ncia, Spain</addr-line></aff><aff id="aff005"><label>5</label><addr-line>CIBER en Epidemiolog&#x000ed;a y Salud P&#x000fa;blica, Madrid, Spain</addr-line></aff><aff id="aff006"><label>6</label><addr-line>Reference Laboratory of Catalonia, Barcelona, Spain</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Landay</surname><given-names>Alan</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Rush University, UNITED STATES</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con"><p><list list-type="simple"><list-item><p><bold>Conceptualization:</bold> JV.</p></list-item><list-item><p><bold>Data curation:</bold> JV RG HK A Gonz&#x000e1;lez EL A Guelar LS.</p></list-item><list-item><p><bold>Formal analysis:</bold> HK AA GD AM.</p></list-item><list-item><p><bold>Funding acquisition:</bold> JV HK.</p></list-item><list-item><p><bold>Investigation:</bold> JV GD.</p></list-item><list-item><p><bold>Methodology:</bold> JV JJH AA GD.</p></list-item><list-item><p><bold>Project administration:</bold> JV HK.</p></list-item><list-item><p><bold>Resources:</bold> JV JPH A Gonz&#x000e1;lez GD.</p></list-item><list-item><p><bold>Software:</bold> AA GD AM.</p></list-item><list-item><p><bold>Supervision:</bold> JV HK AM GD.</p></list-item><list-item><p><bold>Validation:</bold> JJH AA GD AM HK.</p></list-item><list-item><p><bold>Visualization:</bold> JV RG HK GD.</p></list-item><list-item><p><bold>Writing &#x02013; original draft:</bold> JV.</p></list-item><list-item><p><bold>Writing &#x02013; review &#x00026; editing:</bold> JV RG HK GD AM AA.</p></list-item></list>
</p></fn><corresp id="cor001">* E-mail: <email>jvillar@hospitaldelmar.cat</email></corresp></author-notes><pub-date pub-type="epub"><day>7</day><month>4</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>12</volume><issue>4</issue><elocation-id>e0173802</elocation-id><history><date date-type="received"><day>9</day><month>11</month><year>2016</year></date><date date-type="accepted"><day>22</day><month>2</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 Villar-Garc&#x000ed;a et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Villar-Garc&#x000ed;a et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0173802.pdf"/><abstract><p>Dysbalance in gut microbiota has been linked to increased microbial translocation, leading to chronic inflammation in HIV-patients, even under effective HAART. Moreover, microbial translocation is associated with insufficient reconstitution of CD4+T cells, and contributes to the pathogenesis of immunologic non-response. In a double-blind, randomised, placebo-controlled trial, we recently showed that, compared to placebo, 12 weeks treatment with probiotic <italic>Saccharomyces boulardii</italic> significantly reduced plasma levels of bacterial translocation (<italic>Lipopolysaccharide-binding protein</italic> or LBP) and systemic inflammation (IL-6) in 44 HIV virologically suppressed patients, half of whom (n = 22) had immunologic non-response to antiretroviral therapy (&#x0003c;270 CD4+Tcells/&#x003bc;L despite long-term suppressed viral load). The aim of the present study was to investigate if this beneficial effect of the probiotic <italic>Saccharomyces boulardii</italic> is due to modified gut microbiome composition, with a decrease of some species associated with higher systemic levels of microbial translocation and inflammation. In this study, we used 16S rDNA gene amplification and parallel sequencing to analyze the probiotic impact on the composition of the gut microbiome (faecal samples) in these 44 patients randomized to receive oral supplementation with probiotic or placebo for 12 weeks. Compared to the placebo group, in individuals treated with probiotic we observed lower concentrations of some gut species, such as those of the C<italic>lostridiaceae</italic> family, which were correlated with systemic levels of bacterial translocation and inflammation markers. In a sub-study of these patients, we observed significantly higher parameters of microbial translocation (LBP, soluble CD14) and systemic inflammation in immunologic non-responders than in immunologic responders, which was correlated with a relative abundance of specific gut bacterial groups (<italic>Lachnospiraceae</italic> genus and Proteobacteria). Thus, in this work, we propose a new therapeutic strategy using the probiotic yeast <italic>S</italic>. <italic>boulardii</italic> to modify gut microbiome composition. Identifying pro-inflammatory species in the gut microbiome could also be a useful new marker of poor immune response and a new therapeutic target.</p></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100003751</institution-id><institution>Ministerio de Sanidad, Servicios Sociales e Igualdad</institution></institution-wrap></funding-source><award-id>&#x0201c;Grant for independent clinical research 2012&#x0201d; (EC-11-541)</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-2813-8426</contrib-id><name><surname>Villar-Garc&#x000ed;a</surname><given-names>Judit</given-names></name></principal-award-recipient></award-group><funding-statement>This work is supported by a Spanish Health Ministry &#x0201c;Grant for independent clinical research 2012&#x0201d; (EC-11-541) to Judit Villar, the principal investigator, <ext-link ext-link-type="uri" xlink:href="http://www.msssi.gob.es">www.msssi.gob.es</ext-link>. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="5"/><table-count count="1"/><page-count count="15"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Recent studies have shown that gut microbiota is impaired in HIV-patients, even after effective Highly Active Antirretroviral Therapy (HAART), and a large number of disease-associated bacteria have been identified. HIV-infection severely damages the gastrointestinal mucosal barrier resulting in microbial translocation [<xref rid="pone.0173802.ref001" ref-type="bibr">1</xref>&#x02013;<xref rid="pone.0173802.ref002" ref-type="bibr">2</xref>], which in turn leads to continuous systemic inflammation and disease progression despite effective HAART [<xref rid="pone.0173802.ref003" ref-type="bibr">3</xref>&#x02013;<xref rid="pone.0173802.ref006" ref-type="bibr">6</xref>]. Using high-resolution profiling of the bacterial community by 16S rDNA gene amplification and pyrosequencing, previous studies have identified a dysbiotic gut pattern in HIV-infected individuals, characterized by increased microbial translocation, chronic inflammation and hyperactivation of CD4+T cells, despite achieving long-term virologic suppression [<xref rid="pone.0173802.ref007" ref-type="bibr">7</xref>&#x02013;<xref rid="pone.0173802.ref011" ref-type="bibr">11</xref>]. Moreover, microbial translocation is associated with insufficient reconstitution of CD4+T cells, and contributes to the pathogenesis of immunologic non-response [<xref rid="pone.0173802.ref012" ref-type="bibr">12</xref>&#x02013;<xref rid="pone.0173802.ref016" ref-type="bibr">16</xref>]. A recent study have reported that HIV gut microbiome must be controlled for HIV risk factors, and after stratifying for sexual orientation, there was no solid evidence of an HIV-specific dysbiosis, but HIV-1 infection remained consistently associated with reduced bacterial richness and the lowest gut bacterial richness was observed in immunologic non-responders patients [<xref rid="pone.0173802.ref017" ref-type="bibr">17</xref>].</p><p>Recently the intestinal microbiome has been proposed as a novel therapeutic target for reducing chronic inflammation [<xref rid="pone.0173802.ref018" ref-type="bibr">18</xref>&#x02013;<xref rid="pone.0173802.ref019" ref-type="bibr">19</xref>] and various interventions such as pre-probiotics have been proposed to improve the resident gut microbiome [<xref rid="pone.0173802.ref020" ref-type="bibr">20</xref>&#x02013;<xref rid="pone.0173802.ref022" ref-type="bibr">22</xref>]. Since the specific effects of HIV infection on the particular gut bacterial taxa that contributes to chronic immunoactivation are unclear, it seems reasonable to propose treatments to improve the gut bacterial richness and HIV associated immune dysfunction. However, the beneficial effects of probiotics are strain-dependent and not all interventions are equally effective [<xref rid="pone.0173802.ref023" ref-type="bibr">23</xref>&#x02013;<xref rid="pone.0173802.ref025" ref-type="bibr">25</xref>]. <italic>Saccharomyces boulardii</italic> is a probiotic whose clinical efficacy, anti-inflammatory and immunomodulatory effects are supported by extensive previous studies [<xref rid="pone.0173802.ref026" ref-type="bibr">26</xref>&#x02013;<xref rid="pone.0173802.ref030" ref-type="bibr">30</xref>]. We recently demonstrated that treatment with <italic>S</italic>. <italic>boulardii</italic> significantly decreased plasma levels of microbial translocation (<italic>Lipopolysaccharide-binding protein</italic> or LBP) and inflammation parameters such as cytokine IL-6 in 44 HIV-treated patients, half of whom had an immunodiscordant response to antiretroviral therapy [<xref rid="pone.0173802.ref031" ref-type="bibr">31</xref>]. The aim of the present study was to investigate if this beneficial effect of the probiotic <italic>Saccharomyces boulardii</italic> is due to a modification in the gut microbiome composition of this patients, with a decrease in some species associated with higher systemic levels of microbial translocation and inflammation. In this study, we used 16S rDNA tagging to analyze the gut microbiome communities in these 44 patients, to assess the impact of probiotic treatment with <italic>S</italic>. <italic>boulardii</italic> compared to placebo.</p><p>In a sub-study of these patients, we explore if the immunological non-response was associated with higher systemic inflammation and microbial translocation parameters and a distinct gut microbiome pattern.</p></sec><sec id="sec002"><title>Subjects, material and methods</title><sec id="sec003"><title>Study design</title><p>We performed a double-blind randomized, placebo-controlled trial to analyze the composition of the gut microbiota, microbial translocation, and inflammation parameters in 44 chronic HIV-infected patients with undetectable plasma viral load (&#x0003c;20 copies/mL) for at least 2 years and a stable HAART regimen. Half of the patients (n = 22) had already been previously selected as being immunodiscordant or immunological non-responders (INR), defined as individuals with an persistent unfavorable immunologic response (&#x0003c;270 CD4+Tcells/&#x003bc;L despite long-term suppressed viral load), while the other 22 had already been previously selected as immunologic responders (IR: CD4+T count &#x0003e;400 cells/&#x003bc;L). Once the patients had been included in the IR or INR group, they were double-blind randomized to oral supplementation with probiotic <italic>S</italic>. <italic>boulardii</italic> (capsules with 56.5 mg living yeasts, 2 capsules 3 times per day, n = 22), or placebo (2 capsules 3 times per day, n = 22) for 12 weeks. All 44 participants completed the study; none discontinued their participation because of side effects of the treatments or adverse events. (<xref ref-type="fig" rid="pone.0173802.g001">Fig 1</xref>. CONSORT Flow diagram). Markers of microbial translocation and inflammation, immunological and clinical data were collected before and after the intervention (Baseline and week 12), and follow-up visits were conducted until 48 weeks (See &#x0201c;<xref ref-type="supplementary-material" rid="pone.0173802.s001">S1</xref> and <xref ref-type="supplementary-material" rid="pone.0173802.s002">S2</xref> Protocols&#x0201d; Files). We recently reported the plasma findings in these patients [<xref rid="pone.0173802.ref031" ref-type="bibr">31</xref>]. All patients also provided 50gr of stool samples before and after the intervention, which were stored at -80&#x000b0;C within the first 24&#x02013;48 hours; to allow us to compare gut microbiome composition before and after a 12-week treatment with probiotic or placebo. A computer-generated randomization list was used. Randomization was performed by a hospital pharmacist unrelated to the care of the patients, using sequentially numbered containers. The participants and the care providers were blinded after assignment to interventions.</p><fig id="pone.0173802.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0173802.g001</object-id><label>Fig 1</label><caption><title>CONSORT flow diagram.</title></caption><graphic xlink:href="pone.0173802.g001"/></fig><p>The study was approved by the Clinical Research Ethics Committee of Hospital del Mar Medical Research Institute, number 2011/4508, on data 01/Feb/2012, according to the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants before enrollment in the study. Patients were recruited between August 2012-July 2013. The study was registered during the enrollment because it had already been previously notified, registered and approved by the Hospital del Mar Medical Research Institute Ethics Committee. The authors confirm that related trial for this intervention is registered at ClinicalTrials.gov (PROB-VIH, Trial number: NCT01908049). &#x0201c;<xref ref-type="supplementary-material" rid="pone.0173802.s003">S1 Checklist</xref>&#x0201d;</p></sec><sec id="sec004"><title>Microbial translocation markers</title><p>Serum levels of soluble CD14 were quantified using a ELISA kit (Quantikine<sup>&#x02122;</sup>, R&#x00026;D Systems, Minneapolis, MN) on a Quanta-Lyser<sup>&#x02122;</sup> 160 robotic workstation (Inova Diagnostics, San Diego, CA). Serum LBP was measured using the Immulite<sup>&#x02122;</sup> chemiluminescent immunometric assay on its automated analyzer (Immulite One, Siemens Healthcare<sup>&#x000ae;</sup>, Llanberis, UK).</p></sec><sec id="sec005"><title>Inflammation markers</title><p>Milliplex MAP<sup>&#x02122;</sup> was used to analyze IL-6. Hs-CRP and &#x003b2;2 microglobulin were measured using the Immulite One<sup>&#x02122;</sup>, and plasma fibrinogen with HemosIL<sup>&#x02122;</sup> reagents.</p></sec><sec id="sec006"><title>Microbiome taxonomy analyses &#x00026; bioinformatics</title><p>DNA was extracted from frozen stool samples and amplified by PCR targeting 16S gene regions using primers described elsewhere [<xref rid="pone.0173802.ref032" ref-type="bibr">32</xref>]. We performed library preparation followed by Illumina sequencing according to standard protocols described previously [<xref rid="pone.0173802.ref033" ref-type="bibr">33</xref>]. The taxonomic composition of the intestinal microbiota was characterized by grouping sequences into OTUs (Organizational Taxonomic Units). We used the QIIME open source algorithm for handling and interpretation of the data from the raw sequences; following quality assessment of sequence data, we assigned taxonomic affiliations using the RDP_classifier from the Ribosomal Database Project [<xref rid="pone.0173802.ref034" ref-type="bibr">34</xref>].</p></sec><sec id="sec007"><title>Statistical analysis</title><p>No previous data were available to estimate the sample size; thus, for a Type I error rate of 0.05 and a 1-beta risk of 0.20 in a bilateral contrast, we computed that 22 patients were needed per study group to detect statistically significant differences between proportions. The assumed proportions for the power analysis for each group was 0.5. Continuous variables were expressed as the median and interquartile range, and discrete variables as percentages. Categorical variables were described as proportions. The Mann-Whitney U-test was used to compare medians, ANOVA to assess differences in continuous variables, and the Pearson's &#x003c7;<sup>2</sup> test to evaluate the association between categorical variables. We also conducted multivariate logistic regression analysis to study the correlation between microbial translocation and systemic inflammation parameters, and conditional backward stepwise regression analysis at baseline to identify parameters that were correlated with the immunodiscordance. The enter criteria was a p value&#x0003c;0.1. All the variables studied were selected based on the statistical significance. For the analysis of qualitative differences between responders and non-responders, we performed a median recoding of LBP, soluble CD4, &#x003b2;2 microglobuline and fibrinogen; the values obtained were defined as high or low. Statistical analyses were performed using SPSS software version 20.0 (SPSS, Inc., Chicago, IL) and several open source libraries in R (R Core Team 2014. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <ext-link ext-link-type="uri" xlink:href="http://www.R-project.org/">http://www.R-project.org/</ext-link>). The glm (R) function has been used in the logistic regression analysis.</p></sec></sec><sec sec-type="results" id="sec008"><title>Results</title><sec id="sec009"><title>Patient characteristics</title><p>This study included 44 patients. Half of each group were immunological non-responders (INR), the median age was 47.5 years, 84% were male, and the risk factors for acquiring HIV infection were Heterosexual (HTX) (46%), Men who Have Sex with Men (MHSM) (38%) and Injection drug users (IDU) (16%). The profiles of demographic, biological and clinical parameters were similar in the probiotic and placebo groups [<xref rid="pone.0173802.ref031" ref-type="bibr">31</xref>] (&#x0201c;<xref ref-type="supplementary-material" rid="pone.0173802.s005">S1 Table&#x0201d;</xref>). All patients had suppressed viral load for a median of 4.7 years, with NNRTI-based (75%) or PI-based HAART (25%). The median nadir CD4+T was 108 cells/&#x003bc;l, and 41% had AIDS diagnosis.</p></sec><sec id="sec010"><title>Microbial translocation is correlated with systemic inflammation</title><p>We tested for association between microbial translocation measurements and baseline parameters from 44 patients, and observed a statistically significant correlation between LBP levels and plasma levels of soluble CD14 (r = 0.48, p = 0.001), Hs-CRP (r = 0.63, p = 0.0001), &#x003b2;2 microglobulin (r = 0.59, p = 0.0001), Erythrocyte Sedimentation Rate-ESR (r = 0.57, p = 0.0001), Fibrinogen (r = 0.64, p = 0.0001), Cd4 nadir (r = -0.53, p = 0.0001), and IL-6 (r = 0.58, p = 0.0001). Using multivariate logistic regression analysis, we found that LBP was independently correlated with Hs-CRP, ESR and soluble CD14 (&#x0201c;<xref ref-type="supplementary-material" rid="pone.0173802.s006">S2 Table</xref>&#x0201d;).</p></sec><sec id="sec011"><title><italic>Saccharomyces boulardii</italic> produces changes in some gut bacterial communities</title><p>Canonical correspondance analysis shows the high influence of probiotic effect versus the time effect (vertical axis) (<xref ref-type="fig" rid="pone.0173802.g002">Fig 2</xref>). Changes in gut microbiome after the interventions are showed at &#x0201c;<xref ref-type="supplementary-material" rid="pone.0173802.s004">S1 Fig</xref>&#x0201d; (INRs group). After 12 weeks of probiotic treatment, we observed a significant decrease in levels of some Clostridiales species with respect to baseline compared with placebo (<xref ref-type="fig" rid="pone.0173802.g003">Fig 3</xref>). We also observed a significant decreased in <italic>Catenibacterium</italic> communities (2.65 to 0.04, p = 0.00003), and an increase in levels of Megamonas (p = 0.02) and Desulfovibrionales (Proteobacteria) (p = 0.05). These probiotic effects on gut microbiota composition were similar in the INR and IR groups.</p><fig id="pone.0173802.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0173802.g002</object-id><label>Fig 2</label><caption><title>Canonical correspondence analysis.</title></caption><graphic xlink:href="pone.0173802.g002"/></fig><fig id="pone.0173802.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0173802.g003</object-id><label>Fig 3</label><caption><title>Changes in the proportion of Clostridiales after the interventions.</title></caption><graphic xlink:href="pone.0173802.g003"/></fig><p>We then investigated the correlation between these different stool bacterial populations, parameters of microbial translocation and systemic inflammation, and observed a statistically significant correlation between the proportion of Clostridia genera and plasma concentrations of soluble CD14 (r = 0.63, p = 0.03), LBP (r = 0.71, p = 0.009), and IL-6 (r = 0.69, p = 0.0008; <xref ref-type="fig" rid="pone.0173802.g004">Fig 4</xref>). These correlations were present at baseline in INR group but not in the IRs probably because IRs have a lower relative abundance of Clostridiaceae at baseline. The correlations are not statistically significant in probiotic treated group, probably because of a decrease in these bacterial communities due to the probiotic effect (<xref ref-type="fig" rid="pone.0173802.g005">Fig 5</xref>).</p><fig id="pone.0173802.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0173802.g004</object-id><label>Fig 4</label><caption><title>Correlations between relative abundance of Clostridiales and soluble CD14 (4A), LBP (4B) and IL6 (4C) <underline>before</underline> the intervention (INR).</title><p>LBP, Lipopolisaccharide Binding-Proteine; IL6, interleukin-6.</p></caption><graphic xlink:href="pone.0173802.g004"/></fig><fig id="pone.0173802.g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0173802.g005</object-id><label>Fig 5</label><caption><title>Correlations between relative abundance of Clostridiales and soluble CD14 (5A), LBP (5B) and IL6 (5C) <underline>after</underline> probiotic treatment.</title><p>LBP, Lipopolisaccharide Binding-Proteine; IL6, interleukin-6.</p></caption><graphic xlink:href="pone.0173802.g005"/></fig></sec><sec id="sec012"><title>Immunological non-response is associated with higher microbial translocation and the presence of some pro-inflammatory species</title><p>The baseline differences between the INR and IR groups are summarized in <xref ref-type="table" rid="pone.0173802.t001">Table 1</xref>. Quantitative analysis of the baseline data indicates that the following variables showed statistically significant differences between the INR and IR group: age, current CD4+T count, CD4+T nadir, HCV coinfection, LBP and &#x003b2;2 microglobulin levels. The INR groups tended to have higher fibrinogen and soluble CD14 levels. Compared to the IR group, the INR group had a greater proportion of individuals with values greater than the median of LBP (68.2% <italic>vs</italic> 27.3%, p = 0.007); soluble CD14 (72.7% <italic>vs</italic> 40.9%, p = 0.03); &#x003b2;2 microglobuline (66.7% <italic>vs</italic> 33%, p = 0.022) and fibrinogen (65% <italic>vs</italic> 31.8%, p = 0.03).</p><table-wrap id="pone.0173802.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0173802.t001</object-id><label>Table 1</label><caption><title>Differences between Immunological Responders (IR) and Non-Responders (INR).</title></caption><alternatives><graphic id="pone.0173802.t001g" xlink:href="pone.0173802.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="justify" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Responders<break/>(n = 22)</th><th align="left" rowspan="1" colspan="1">Non&#x02013;Responders<break/>(n = 22)</th><th align="justify" rowspan="1" colspan="1"><italic>p-value</italic></th></tr></thead><tbody><tr><td align="justify" rowspan="1" colspan="1"><bold>Demographics</bold></td><td align="justify" rowspan="1" colspan="1"/><td align="justify" rowspan="1" colspan="1"/><td align="justify" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;Age (years) [SD]</td><td align="left" rowspan="1" colspan="1">44 (37&#x02013;49)</td><td align="left" rowspan="1" colspan="1">52 (47&#x02013;57)</td><td align="left" rowspan="1" colspan="1">0.014</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;Male [n (%)]</td><td align="justify" rowspan="1" colspan="1">21 (95.5)</td><td align="justify" rowspan="1" colspan="1">16 (72.7)</td><td align="justify" rowspan="1" colspan="1">0.042</td></tr><tr><td align="justify" rowspan="1" colspan="1"><bold>HIV infection</bold></td><td align="justify" rowspan="1" colspan="1"/><td align="justify" rowspan="1" colspan="1"/><td align="justify" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;Risk factor [n (%)]</td><td align="justify" rowspan="1" colspan="1"/><td align="justify" rowspan="1" colspan="1"/><td align="justify" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;&#x02003;IDU</td><td align="justify" rowspan="1" colspan="1">0 (0)</td><td align="justify" rowspan="1" colspan="1">6 (100)</td><td align="justify" rowspan="1" colspan="1">0.03</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;&#x02003;MHSM</td><td align="justify" rowspan="1" colspan="1">12 (70.6)</td><td align="justify" rowspan="1" colspan="1">5 (29.4)</td><td align="justify" rowspan="1" colspan="1">0.06</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;&#x02003;HTX</td><td align="justify" rowspan="1" colspan="1">10 (50)</td><td align="justify" rowspan="1" colspan="1">10 (50)</td><td align="justify" rowspan="1" colspan="1">1</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;Time with viral load &#x0003c;50 copies/ml (years) [median (IQR)]</td><td align="justify" rowspan="1" colspan="1">4.5 (3&#x02013;9.25)</td><td align="justify" rowspan="1" colspan="1">5 (3.75&#x02013;10)</td><td align="justify" rowspan="1" colspan="1">0.463</td></tr><tr><td align="justify" rowspan="1" colspan="1"><italic>Nadir</italic> CD4 cell count (/ml) [median (IQR)]</td><td align="justify" rowspan="1" colspan="1">244 (105&#x02013;293)</td><td align="justify" rowspan="1" colspan="1">47.5 (9&#x02013;113.75)</td><td align="justify" rowspan="1" colspan="1">0.000</td></tr><tr><td align="justify" rowspan="1" colspan="1"><italic>Zenith</italic> viral load (log10) [median (IQR)]</td><td align="left" rowspan="1" colspan="1">4.88 (4.58&#x02013;5.38)</td><td align="left" rowspan="1" colspan="1">5.06 (4.39&#x02013;5.41)</td><td align="left" rowspan="1" colspan="1">0.770</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;HCV co-infection [n (%)]</td><td align="justify" rowspan="1" colspan="1">0 (0)</td><td align="justify" rowspan="1" colspan="1">8 (100)</td><td align="justify" rowspan="1" colspan="1">0.002</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;Current ART [n (%)]</td><td align="justify" rowspan="1" colspan="1"/><td align="justify" rowspan="1" colspan="1"/><td align="justify" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;&#x02003;NNRTI</td><td align="justify" rowspan="1" colspan="1">22 (68.8%)</td><td align="justify" rowspan="1" colspan="1">10 (31.3%)</td><td align="justify" rowspan="1" colspan="1">0.000</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;&#x02003;PI</td><td align="justify" rowspan="1" colspan="1">0</td><td align="justify" rowspan="1" colspan="1">11 (52.4%)</td><td align="justify" rowspan="1" colspan="1">0.000</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;Absolute CD4T-count (cells/&#x003bc;l) [median (IQR)]</td><td align="left" rowspan="1" colspan="1">483 (413&#x02013;630)</td><td align="left" rowspan="1" colspan="1">219 (169&#x02013;266)</td><td align="left" rowspan="1" colspan="1">0.000</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;Absolute CD8T-count (cells/&#x003bc;l) [median (IQR)]</td><td align="left" rowspan="1" colspan="1">699.5(472.5&#x02013;860.5)</td><td align="left" rowspan="1" colspan="1">594 (353&#x02013;781)</td><td align="left" rowspan="1" colspan="1">0.199</td></tr><tr><td align="justify" rowspan="1" colspan="1"><bold>Microbial translocation parameters</bold> [median (IQR)]</td><td align="justify" rowspan="1" colspan="1"/><td align="justify" rowspan="1" colspan="1"/><td align="justify" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;LBP <italic>(pg/mL)</italic></td><td align="left" rowspan="1" colspan="1">5.65 (5.2&#x02013;6.5)</td><td align="left" rowspan="1" colspan="1">7.4 (6.1&#x02013;8.7)</td><td align="left" rowspan="1" colspan="1">0.011</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;Soluble CD14 (&#x003bc;g/mL)</td><td align="left" rowspan="1" colspan="1">1.43 (1.31&#x02013;1.93)</td><td align="left" rowspan="1" colspan="1">1.69 (1.55&#x02013;2.11)</td><td align="left" rowspan="1" colspan="1">0.082</td></tr><tr><td align="justify" rowspan="1" colspan="1"><bold>Inflammation parameters</bold>[median (IQR)]</td><td align="justify" rowspan="1" colspan="1"/><td align="justify" rowspan="1" colspan="1"/><td align="justify" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;Hs-CRP(<italic>mg/dl)</italic></td><td align="left" rowspan="1" colspan="1">0.22 (0.07&#x02013;0.35)</td><td align="left" rowspan="1" colspan="1">0.16 (0.07&#x02013;0.40)</td><td align="left" rowspan="1" colspan="1">0.874</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;IL -6<italic>(pg/mL)</italic></td><td align="left" rowspan="1" colspan="1">1.85 (0.7&#x02013;2.85)</td><td align="left" rowspan="1" colspan="1">2.7 (1.02&#x02013;40.15)</td><td align="left" rowspan="1" colspan="1">0.466</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;Ig E (kU/L)</td><td align="left" rowspan="1" colspan="1">48.9 (16.8&#x02013;157)</td><td align="left" rowspan="1" colspan="1">115 (21.6&#x02013;360)</td><td align="left" rowspan="1" colspan="1">0.467</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;Fibrinogen (mg/dl)</td><td align="justify" rowspan="1" colspan="1">257.5 (219&#x02013;279)</td><td align="justify" rowspan="1" colspan="1">293.5(259.5&#x02013;324)</td><td align="justify" rowspan="1" colspan="1">0.062</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;TNF-&#x003b1;<italic>(pg/mL)</italic></td><td align="left" rowspan="1" colspan="1">10.9 (8.7&#x02013;12.3)</td><td align="left" rowspan="1" colspan="1">12.7 (7.8&#x02013;16.9)</td><td align="left" rowspan="1" colspan="1">0.190</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;ESR (mm/h)</td><td align="justify" rowspan="1" colspan="1">7 (2&#x02013;10.5)</td><td align="justify" rowspan="1" colspan="1">10 (6&#x02013;16.5)</td><td align="justify" rowspan="1" colspan="1">0.100</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;Vit D 25 OH (ng/mL)</td><td align="justify" rowspan="1" colspan="1">30.97(20.07&#x02013;0.33)</td><td align="justify" rowspan="1" colspan="1">37.04 (24.6&#x02013;42.48)</td><td align="justify" rowspan="1" colspan="1">0.253</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;&#x003b2;2microglobuline (&#x003bc;g/mL)</td><td align="justify" rowspan="1" colspan="1">1.7 (1.54&#x02013;2.06)</td><td align="justify" rowspan="1" colspan="1">2.12 (1.93&#x02013;2.86)</td><td align="justify" rowspan="1" colspan="1">0.002</td></tr><tr><td align="justify" rowspan="1" colspan="1"><bold>Gut microbiome composition</bold> (Relative abundance [%])</td><td align="justify" rowspan="1" colspan="1"/><td align="justify" rowspan="1" colspan="1"/><td align="justify" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;<italic>Lachnospiraceae</italic> (Clostridia)</td><td align="justify" rowspan="1" colspan="1">0.017%</td><td align="justify" rowspan="1" colspan="1">0.093%</td><td align="justify" rowspan="1" colspan="1">0.03</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;Proteobacteria</td><td align="justify" rowspan="1" colspan="1">0.053%</td><td align="justify" rowspan="1" colspan="1">0.248%</td><td align="justify" rowspan="1" colspan="1">0.06</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>ART, antiretroviral therapy; PI, protease inhibitor; NNRTI, non-nucleoside; reverse transcriptase inhibitor; LBP, <italic>Lipopolysaccharide-binding protein</italic>; sCD14, soluble CD14; hs-CRP, high sensitivity C-reactive protein; IL-6, Interleukin 6; ESR, Erythrocyte Sedimentation Rate; IQR, interquartile range.</p></fn></table-wrap-foot></table-wrap><p>High LBP was associated with being an INR (Relative Risk = 5.71; 95% CI = 1.56&#x02013;20.93; p = 0.015) and in the conditional backward stepwise regression analysis, high LBP was the only variable that could explain immunological non-response (OR = 6.22, 95% CI = 1.63&#x02013;23.75, p = 0.007) (&#x0201c;<xref ref-type="supplementary-material" rid="pone.0173802.s007">S3 Table</xref>&#x0201d;).</p><p>Analyzing gut microbiome composition at baseline, we observed a higher proportion of some Firmicutes species (Clostridia) in the INR group than in the IR group. The proportion of Proteobacteria was higher in immunodiscordant patients; the proportion of <italic>Lachnospiraceae</italic> genera was significantly higher in the INR group (OR = 3.4, p = 0.05) (&#x0201c;<xref ref-type="supplementary-material" rid="pone.0173802.s008">S4 Table</xref>&#x0201d;).</p></sec></sec><sec sec-type="conclusions" id="sec013"><title>Discussion</title><p>This is the first clinical trial to use 16S rDNA sequencing to analyze changes in gut microbiome composition following treatment with <italic>Saccharomyces boulardii</italic>, and how these changes are correlated with microbial translocation and inflammation in HIV patients.</p><p>Microbial imbalance in the gut has been associated with increased microbial translocation, leading to chronic inflammation. In line with this, various microbial communities resident in the gut are correlated with plasma bacterial translocation markers (soluble CD14 and LBP) and pro-inflammatory cytokine interleukin-6 [<xref rid="pone.0173802.ref010" ref-type="bibr">10</xref>&#x02013;<xref rid="pone.0173802.ref011" ref-type="bibr">11</xref>,<xref rid="pone.0173802.ref035" ref-type="bibr">35</xref>]. We recently reported a significant reduction in LBP and IL-6 levels in a small cohort of HAART-treated HIV patients supplemented with 12 weeks treatment with probiotic <italic>S</italic>. <italic>boulardii</italic> compared to placebo [<xref rid="pone.0173802.ref031" ref-type="bibr">31</xref>]. Here, we take a step further and use 16S rDNA tagging and high throughput sequencing to analyze microbiome profiles before and after the intervention, and to evaluate whether some predominant species are associated with increased bacterial translocation, systemic inflammation and poor immune response in these patients.</p><p>Following probiotic treatment, we observed a significant decrease in some Clostridiales, such as <italic>Clostridiaceae</italic> and <italic>Catenibacterium</italic> communities. Previous studies have used PCR or FISH techniques, rather than 16S rDNA sequencing, to evaluate the effects of supplementation with specific prebiotics in HAART-na&#x000ef;ve infected HIV adults [<xref rid="pone.0173802.ref021" ref-type="bibr">21</xref>] and supplementation with probiotic <italic>S</italic>.<italic>boulardii</italic> in HIV-negative adults with enteritis [<xref rid="pone.0173802.ref036" ref-type="bibr">36</xref>]; these studies reported a consequent reduction in concentrations of pathogenic clostridia-related species, which are considered to be pro-inflammatory mucotropic bacteria, although these authors did not evaluate if this was correlated with a decrease in systemic inflammation. Recent studies have reported a higher proportion of <italic>Catenibacterium</italic> in HIV patients than in healthy individuals [<xref rid="pone.0173802.ref009" ref-type="bibr">9</xref>,<xref rid="pone.0173802.ref011" ref-type="bibr">11</xref>]. <italic>Catenibacterium</italic> is a Gram-positive, non-spore-forming and anaerobic genus from the family of Erysipelotrichidae. Taxa in this family were the most enriched [<xref rid="pone.0173802.ref007" ref-type="bibr">7</xref>], or a significant enrichment was reported [<xref rid="pone.0173802.ref008" ref-type="bibr">8</xref>&#x02013;<xref rid="pone.0173802.ref009" ref-type="bibr">9</xref>], in the untreated HIV-infected subjects compared to HIV-uninfected individuals and was correlated with markers of microbial translocation and systemic inflammation in HIV patients [<xref rid="pone.0173802.ref008" ref-type="bibr">8</xref>]. In our study, the concentration of <italic>Catenibacterium</italic>, which have also been associated with other chronic diseases [<xref rid="pone.0173802.ref037" ref-type="bibr">37</xref>&#x02013;<xref rid="pone.0173802.ref039" ref-type="bibr">39</xref>], also decreased following probiotic treatment.</p><p>We observed a relationship between bacterial translocation and various parameters of systemic inflammation. These data are consistent with previous studies demonstrating, in both treated and untreated HIV patients, a direct correlation between systemic parameters of bacterial translocation, and chronic immune activation and disease progression [<xref rid="pone.0173802.ref040" ref-type="bibr">40</xref>&#x02013;<xref rid="pone.0173802.ref048" ref-type="bibr">48</xref>]. Furthermore, we found significant correlation between some bacterial taxa (Clostridia) and parameters of microbial translocation and systemic inflammation in immunological non-responders group (INR). Recent studies also have demonstrated a statistically significant correlation between some species of Clostridia, including <italic>Lachnospiraceae</italic>, and increased systemic immune activation parameters (TNF) in HIV-infected patients [<xref rid="pone.0173802.ref011" ref-type="bibr">11</xref>]. While the immunologic driving factors of gut dysbiosis related to HIV infection are likely to be complex interestingly, our study showed a significant reduction in these bacterial communities following probiotic treatment.</p><p>HIV-patients with deficient CD4+Tcell count recovery despite HAART have been defined as Immunological non-responders (INRs), and are estimated to account for up to 30% of all treated HIV-infected subjects. This is relevant because this subpopulation is associated with higher morbi-mortality. This phenomenon has been widely studied using different approaches, and its pathogenesis is known to be related to older age, nadir CD4 T-cell count, reduced thymic function, co-infection with hepatotropic viruses, and multiple genetic variants [<xref rid="pone.0173802.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0173802.ref013" ref-type="bibr">13</xref>]. However, the ultimate cause of the discordant response is excessive CD4 T-cell destruction due to CD4+T hyperactivation [<xref rid="pone.0173802.ref014" ref-type="bibr">14</xref>], residual viral replication, and persistent antigenic stimulation due to microbial translocation. HAART-treated individuals have been reported to show an inverse correlation between levels of microbial translocation and sustained failure on CD4+T cell reconstitution [<xref rid="pone.0173802.ref015" ref-type="bibr">15</xref>,<xref rid="pone.0173802.ref016" ref-type="bibr">16</xref>]. A history of more advanced immunosuppression and the resulting damage to gut immunity and integrity are thought to be an important factor in the differences observed between groups in gut microbiome and markers of bacterial translocation and inflammation [<xref rid="pone.0173802.ref049" ref-type="bibr">49</xref>&#x02013;<xref rid="pone.0173802.ref051" ref-type="bibr">51</xref>]. Our results are consistent with these findings, and extend them by comparing the composition of the gut microbial community in immunological responders and non-responders. Interestingly, the relative abundance of specific gut bacterial groups in INR patients is associated with greater bacterial translocation. Recent studies have shown that Proteobacteria, which are over-represented in our group of INRs, are responsible for much of the translocation after SIV-infection [<xref rid="pone.0173802.ref052" ref-type="bibr">52</xref>]; although the mechanisms remain unknown, Brenchley <italic>et al</italic>.[<xref rid="pone.0173802.ref053" ref-type="bibr">53</xref>] suggested their motility, high metabolic rate and possession of immune evasion genes as posibble reasons. Identifying gut species that contribute to the pathogenesis of immunologic non-response and persistent immune activation could be a new diagnostic and therapeutic tool in this group of HIV-patients with an increased risk of clinical progression and death.</p><p>The multiple anti-inflammatory mechanisms produced by <italic>S</italic>. <italic>boulardii</italic> provide molecular explanations to support its effectiveness in intestinal inflammatory states [<xref rid="pone.0173802.ref030" ref-type="bibr">30</xref>]. It has also been demonstrated that <italic>S</italic>. <italic>boulardii</italic> increases absolute numbers of the main habitual fermenting bacterial groups, and decreases concentrations of mucotropic occasional bacterial communities [<xref rid="pone.0173802.ref054" ref-type="bibr">54</xref>]. Several mechanisms of action have been identified directed against the host and pathogenic microorganisms, suppressing &#x0201c;bacteria overgrowth&#x0201d; and host cell adherence [<xref rid="pone.0173802.ref030" ref-type="bibr">30</xref>]. One limitation of this study is that, since <italic>S</italic>. <italic>boulardii</italic> is a yeast, we did not perform 16S rDNA gene amplification and parallel sequencing to demonstrate colonization by the probiotic, or changes in the gut mycobiome. A decrease in some dysbiotic bacterial genera, replacement of inflammogenic yeast and/or improved functional biostructure of colonic microbiota following <italic>S</italic>. <italic>boulardii</italic> treatment may prevent microbial translocation [<xref rid="pone.0173802.ref054" ref-type="bibr">54</xref>], although our study was not designed to determine the mechanism through which changes in gut microbiome composition alter its functional anatomy, metabolomics or mycobiome. Our study has some of the limitations of other studies in this topic. All are small works, and more extensive studies with better tools than 16s sequencing are needed before drawing definitive conclusions, including selection of the patients who could best respond to the probiotic treatment, as well as the doses and duration of the therapy. However, given the increasingly widespread use of metabolomic and metagenomic techniques, analysis of gut bacterial contents could be used in the future as a marker of a dysbiotic microbiome that contributes to chronic systemic inflammation and HIV progression. More importantly, the gut microbiome can be modified using certain strains of probiotics to generate a less pro-inflammatory profile; this new therapeutic target is worthy of further exploration.</p></sec><sec sec-type="conclusions" id="sec014"><title>Conclusions</title><p>We observed a change in gut microbiome composition following probiotic treatment (<italic>S</italic>. <italic>boulardii</italic>), with a decrease in some species which are directly correlated with systemic levels of microbial translocation and inflammation. The use of specific probiotics could be a new therapeutic strategy for HIV patients. In addition, our data suggest that identifying pro-inflammatory species in the gut microbiome could be a new marker of poor immune response.</p></sec><sec sec-type="supplementary-material" id="sec015"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0173802.s001"><label>S1 Protocol</label><caption><p>(DOC)</p></caption><media xlink:href="pone.0173802.s001.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0173802.s002"><label>S2 Protocol</label><caption><p>(DOC)</p></caption><media xlink:href="pone.0173802.s002.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0173802.s003"><label>S1 Checklist</label><caption><p>(DOC)</p></caption><media xlink:href="pone.0173802.s003.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0173802.s004"><label>S1 Fig</label><caption><title>Changes in gut microbiome after the interventions (INRs group).</title><p>INR, immunologic non-responders.</p><p>(TIF)</p></caption><media xlink:href="pone.0173802.s004.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0173802.s005"><label>S1 Table</label><caption><title>Baseline characteristics of the patients.</title><p>ART, antiretroviral therapy; PI, protease inhibitor; NNRTI, nonnucleoside; reverse transcriptase inhibitor; LBP, Lipopolisaccharide Binding-Proteine; sCD14, soluble CD14; hs-CRP, high sensitivity C-reactive protein; ESR, Erythrocyte Sedimentation Rate; IQR, interquartile range.</p><p>(DOCX)</p></caption><media xlink:href="pone.0173802.s005.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0173802.s006"><label>S2 Table</label><caption><title>LBP Multivariate logistic regression analysis.</title><p>LBP, Lipopolisaccharide Binding-Proteine; sCD14, soluble CD14, hs-CRP, high sensitivity C-reactive protein.</p><p>(DOCX)</p></caption><media xlink:href="pone.0173802.s006.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0173802.s007"><label>S3 Table</label><caption><title>Backward stepwise logistic regression analysis.</title><p>LBP_basal, Lipopolisaccharide Binding-Proteine at baseline; sCD14, soluble CD14; &#x003b2;2microglob, Beta 2 microglobuline.</p><p>(DOCX)</p></caption><media xlink:href="pone.0173802.s007.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0173802.s008"><label>S4 Table</label><caption><title>INR logistic regression results.</title><p>(CSV)</p></caption><media xlink:href="pone.0173802.s008.csv"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pone.0173802.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Brenchley</surname><given-names>JM</given-names></name>, <name><surname>Price</surname><given-names>DA</given-names></name>, <name><surname>Schacker</surname><given-names>TW</given-names></name>, <name><surname>Asher</surname><given-names>TE</given-names></name>, <name><surname>Silvestri</surname><given-names>G</given-names></name>, <name><surname>Douek</surname><given-names>DC</given-names></name>, <etal>et al</etal>
<article-title>Microbial translocation is a cause of systemic immune activation in chronic HIV infection</article-title>. <source>Nat Med</source>
<year>2006</year>; <volume>12</volume>(<issue>12</issue>): <fpage>1365</fpage>&#x02013;<lpage>1371</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nm1511">10.1038/nm1511</ext-link></comment>
<pub-id pub-id-type="pmid">17115046</pub-id></mixed-citation></ref><ref id="pone.0173802.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Nazli</surname><given-names>A</given-names></name>, <name><surname>Chan</surname><given-names>O</given-names></name>, <name><surname>Dobson-Belaire</surname><given-names>WN</given-names></name>, <name><surname>Gray-Owen</surname><given-names>SD</given-names></name>, <name><surname>Arsenault</surname><given-names>AL</given-names></name>, <name><surname>Kaushic</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation</article-title>, <source>PLoS Pathogens</source>
<year>2010</year>; <volume>6</volume>(<issue>4</issue>):<fpage>e1000852</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.ppat.1000852">10.1371/journal.ppat.1000852</ext-link></comment>
<pub-id pub-id-type="pmid">20386714</pub-id></mixed-citation></ref><ref id="pone.0173802.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Nowroozalizadeh</surname><given-names>S</given-names></name>, <name><surname>M&#x000e5;nsson</surname><given-names>F</given-names></name>, <name><surname>da Silva</surname><given-names>Z</given-names></name>, <name><surname>Norrgren</surname><given-names>H</given-names></name>, <name><surname>Holmgren</surname><given-names>B</given-names></name>, <name><surname>Jansson</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Microbial translocation correlates with the severity of both HIV-1 and HIV-2 infections</article-title>. <source>J Infect Dis</source>. <year>2010</year>; <volume>201</volume>(<issue>8</issue>):<fpage>1150</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="pmid">20199244</pub-id></mixed-citation></ref><ref id="pone.0173802.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Wallet</surname><given-names>MA</given-names></name>, <name><surname>Rodriguez</surname><given-names>CA</given-names></name>, <name><surname>Yin</surname><given-names>L</given-names></name>, <name><surname>Saporta</surname><given-names>S</given-names></name>, <name><surname>Chinratanapisit</surname><given-names>S</given-names></name>, <name><surname>Hou</surname><given-names>W</given-names></name>, <etal>et al</etal>
<article-title>Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy</article-title>. <source>AIDS2010</source>; <volume>24</volume>(<issue>9</issue>):<fpage>1281</fpage>&#x02013;<lpage>90</lpage>.</mixed-citation></ref><ref id="pone.0173802.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Tincati</surname><given-names>C</given-names></name>, <name><surname>Biasin</surname><given-names>M</given-names></name>, <name><surname>Bandera</surname><given-names>A</given-names></name>, <name><surname>Violin</surname><given-names>M</given-names></name>, <name><surname>Marchetti</surname><given-names>G</given-names></name>, <name><surname>Gori</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Early initiation of highly active antiretroviral therapy fails to reverse immunovirological abnormalities in gut-associated lymphoid tissue induced by acute HIV infection</article-title>. <source>Antivir Ther</source>. <year>2009</year>; <volume>14</volume>(<issue>3</issue>):<fpage>321</fpage>&#x02013;<lpage>330</lpage>. <pub-id pub-id-type="pmid">19474466</pub-id></mixed-citation></ref><ref id="pone.0173802.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Cassol</surname><given-names>E</given-names></name>, <name><surname>Malfeld</surname><given-names>S</given-names></name>, <name><surname>Mahasha</surname><given-names>P</given-names></name>, <name><surname>Alfano</surname><given-names>M</given-names></name>, <name><surname>Poli</surname><given-names>G</given-names></name>, <name><surname>Rossouw</surname><given-names>T</given-names></name>, <etal>et al</etal>
<article-title>Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy</article-title>. <source>J Infect Dis</source>. <year>2010</year>; <volume>202</volume>(<issue>5</issue>):<fpage>723</fpage>&#x02013;<lpage>33</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1086/655229">10.1086/655229</ext-link></comment>
<pub-id pub-id-type="pmid">20629534</pub-id></mixed-citation></ref><ref id="pone.0173802.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Vujkovic-Cvijin</surname><given-names>I</given-names></name>, <name><surname>Dunham</surname><given-names>RM</given-names></name>, <name><surname>Iwai</surname><given-names>S</given-names></name>, <name><surname>Hunt</surname><given-names>PW</given-names></name>, <name><surname>Lynch</surname><given-names>SV</given-names></name>, <name><surname>McCune</surname><given-names>JM</given-names></name>, <etal>et al</etal>
<article-title>Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism</article-title>, <source>Science Translational Medicine</source>
<year>2013</year>; <volume>5</volume>(<issue>193</issue>):<fpage>193ra91</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1126/scitranslmed.3006438">10.1126/scitranslmed.3006438</ext-link></comment>
<pub-id pub-id-type="pmid">23843452</pub-id></mixed-citation></ref><ref id="pone.0173802.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Dinh</surname><given-names>DM</given-names></name>, <name><surname>Volpe</surname><given-names>GE</given-names></name>, <name><surname>Duffalo</surname><given-names>C</given-names></name>,<name><surname>Tai</surname><given-names>AK</given-names></name>, <name><surname>Kane</surname><given-names>AV</given-names></name>, <name><surname>Ward</surname><given-names>HD</given-names></name>, <etal>et al</etal>
<article-title>Intestinal microbiota, microbial translocation, and systemic inflammation in chronic HIV infection</article-title>. <source>J Infect Dis</source>. <year>2015</year>; <volume>211</volume>(<issue>1</issue>):<fpage>19</fpage>&#x02013;<lpage>27</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/infdis/jiu409">10.1093/infdis/jiu409</ext-link></comment>
<pub-id pub-id-type="pmid">25057045</pub-id></mixed-citation></ref><ref id="pone.0173802.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Lozupone</surname><given-names>CA</given-names></name>, <name><surname>Rhodes</surname><given-names>ME</given-names></name>, <name><surname>Neff</surname><given-names>CP</given-names></name>, <name><surname>Fontenot</surname><given-names>AP</given-names></name>, <name><surname>Campbell</surname><given-names>TB</given-names></name>, and <name><surname>Palmer</surname><given-names>BE</given-names></name>. <article-title>HIV-induced alteration in gut microbiota: driving factors, consequences, and effects of antiretroviral therapy</article-title>. <source>Gut Microbes</source>
<year>2014</year>; <volume>5</volume>(<issue>4</issue>):<fpage>562</fpage>&#x02013;<lpage>570</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.4161/gmic.32132">10.4161/gmic.32132</ext-link></comment>
<pub-id pub-id-type="pmid">25078714</pub-id></mixed-citation></ref><ref id="pone.0173802.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Ellis</surname><given-names>CL</given-names></name>, <name><surname>Ma</surname><given-names>ZM</given-names></name>, <name><surname>Mann</surname><given-names>SK</given-names></name>, <name><surname>Miller</surname><given-names>CJ</given-names></name>, <name><surname>Pollard</surname><given-names>RB</given-names></name>, <name><surname>Asmuth</surname><given-names>DM</given-names></name>, <etal>et al</etal>
<article-title>Molecular Characterization of Stool Microbiota in HIV-Infected Subjects by Panbacterial and Order-Level 16S Ribosomal DNA (rDNA) Quantification and Correlations with Immune Activation</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2011</year>; <volume>57</volume>(<issue>5</issue>):<fpage>363</fpage>&#x02013;<lpage>370</lpage>. <pub-id pub-id-type="pmid">21436711</pub-id></mixed-citation></ref><ref id="pone.0173802.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Mutlu</surname><given-names>EA</given-names></name>, <name><surname>Keshavarzian</surname><given-names>A</given-names></name>, <name><surname>Losurdo</surname><given-names>J</given-names></name>, <name><surname>Gorenz</surname><given-names>A</given-names></name>, <name><surname>Burns</surname><given-names>C</given-names></name>, <name><surname>Landay</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>A compositional look at the human gastrointestinal microbiome and immune activation parameters in HIV infected subjects</article-title>, <source>PLoSPathogens</source>
<year>2014</year>; <volume>10</volume>(<issue>2</issue>):<fpage>IDe1003829</fpage>.</mixed-citation></ref><ref id="pone.0173802.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Benveniste</surname><given-names>O</given-names></name>, <name><surname>Flahault</surname><given-names>A</given-names></name>, <name><surname>Sterkers</surname><given-names>G</given-names></name>, <name><surname>Simon</surname><given-names>A</given-names></name>, <name><surname>Ameisen</surname><given-names>JC</given-names></name>, <name><surname>Leport</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads</article-title>. <source>J Infect Dis</source>. <year>2005</year>; <volume>191</volume> (<issue>10</issue>):<fpage>1670</fpage>&#x02013;<lpage>1679</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1086/429670">10.1086/429670</ext-link></comment>
<pub-id pub-id-type="pmid">15838794</pub-id></mixed-citation></ref><ref id="pone.0173802.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Gazzola</surname><given-names>L</given-names></name>, <name><surname>Tincati</surname><given-names>C</given-names></name>, <name><surname>Bellistri</surname><given-names>GM</given-names></name>, <name><surname>Monforte</surname><given-names>A</given-names></name>, <name><surname>Marchetti</surname><given-names>G</given-names></name>. <article-title>The absence of CD4R T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options</article-title>. <source>Clin Infect Dis</source>
<year>2009</year>; <volume>48</volume>(<issue>3</issue>):<fpage>328</fpage>&#x02013;<lpage>337</lpage>. <pub-id pub-id-type="pmid">19123868</pub-id></mixed-citation></ref><ref id="pone.0173802.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Massanella</surname><given-names>M</given-names></name>, <name><surname>Negredo</surname><given-names>E</given-names></name>, <name><surname>Perez-Alvarez</surname><given-names>N</given-names></name>, <name><surname>Puig</surname><given-names>J</given-names></name>, <name><surname>Ruiz-Hernandez</surname><given-names>R</given-names></name>, <name><surname>Bofill</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART</article-title>. <source>AIDS</source>
<year>2010</year>; <volume>24</volume>(<issue>7</issue>):<fpage>959</fpage>&#x02013;<lpage>68</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/QAD.0b013e328337b957">10.1097/QAD.0b013e328337b957</ext-link></comment>
<pub-id pub-id-type="pmid">20177358</pub-id></mixed-citation></ref><ref id="pone.0173802.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Marchetti</surname><given-names>G</given-names></name>, <name><surname>Bellistri</surname><given-names>GM</given-names></name>, <name><surname>Borghi</surname><given-names>E</given-names></name>, <name><surname>Tincati</surname><given-names>C</given-names></name>, <name><surname>Ferramosca</surname><given-names>S</given-names></name>, <name><surname>La Francesca</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy</article-title>. <source>AIDS</source>
<year>2010</year>; <volume>22</volume>(<issue>15</issue>):<fpage>2035</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="pone.0173802.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Merlini</surname><given-names>E</given-names></name>, <name><surname>Bai</surname><given-names>F</given-names></name>, <name><surname>Bellistri</surname><given-names>GM</given-names></name>, <name><surname>Tincati</surname><given-names>C</given-names></name>, <name><surname>d&#x02019;Arminio Monforte</surname><given-names>A</given-names></name>, <name><surname>Marchetti</surname><given-names>G</given-names></name>. <article-title>Evidence for polymicrobic flora translocating in peripheral blood of HIV-infected patients with poor immune response to antiretroviral therapy</article-title>. <source>PLoS One</source>
<year>2011</year>; <volume>6</volume>(<issue>4</issue>):<fpage>e18580</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0018580">10.1371/journal.pone.0018580</ext-link></comment>
<pub-id pub-id-type="pmid">21494598</pub-id></mixed-citation></ref><ref id="pone.0173802.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Noguera-Julian</surname><given-names>M</given-names></name>, <name><surname>Rocafort</surname><given-names>M</given-names></name>, <name><surname>Guill&#x000e9;n</surname><given-names>Y</given-names></name>, <name><surname>Rivera</surname><given-names>J</given-names></name>, <name><surname>Casadell&#x000e0;</surname><given-names>M</given-names></name>, <name><surname>Nowak</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>Gut Microbiota Linked to Sexual Preference and HIV Infection</article-title>. <source>EBioMedicine</source>. <year>2016</year>
<month>1</month>
<day>28</day>;<volume>5</volume>:<fpage>135</fpage>&#x02013;<lpage>46</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ebiom.2016.01.032">10.1016/j.ebiom.2016.01.032</ext-link></comment>
<pub-id pub-id-type="pmid">27077120</pub-id></mixed-citation></ref><ref id="pone.0173802.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Rajasuriar</surname><given-names>R</given-names></name>, <name><surname>Khoury</surname><given-names>G</given-names></name>, <name><surname>Kamarulzaman</surname><given-names>A</given-names></name>, <name><surname>French</surname><given-names>MA</given-names></name>, <name><surname>Cameron</surname><given-names>PU</given-names></name>, <name><surname>Lewin</surname><given-names>SR</given-names></name>. <article-title>Persistent immune activation in chronic HIV infection: do any interventions work?</article-title>
<source>AIDS</source>
<year>2013</year>; <volume>27</volume> (<issue>8</issue>):<fpage>1199</fpage>&#x02013;<lpage>208</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/QAD.0b013e32835ecb8b">10.1097/QAD.0b013e32835ecb8b</ext-link></comment>
<pub-id pub-id-type="pmid">23324661</pub-id></mixed-citation></ref><ref id="pone.0173802.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Assimakopoulos</surname><given-names>SF</given-names></name>, <name><surname>Dimitropoulou</surname><given-names>D</given-names></name>, <name><surname>Marangos</surname><given-names>M</given-names></name> and <name><surname>Gogos</surname><given-names>CA</given-names></name>. <article-title>Intestinal barrier dysfunction in HIV infection: pathophysiology, clinical implications and potential therapies</article-title>. <source>Infection</source>
<year>2014</year>; <volume>42</volume>(<issue>6</issue>):<fpage>951</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s15010-014-0666-5">10.1007/s15010-014-0666-5</ext-link></comment>
<pub-id pub-id-type="pmid">25070877</pub-id></mixed-citation></ref><ref id="pone.0173802.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Hummelen</surname><given-names>R</given-names></name>, <name><surname>Changalucha</surname><given-names>J</given-names></name>, <name><surname>Butamanya</surname><given-names>NL</given-names></name>, <name><surname>Cook</surname><given-names>A</given-names></name>, <name><surname>Habbema</surname><given-names>JD</given-names></name>, <name><surname>Reid</surname><given-names>G</given-names></name>, <etal>et al</etal>
<article-title>Effect of 25 weeks probiotic supplementation on immune function of HIV patients</article-title>. <source>Gut Microbes</source>
<year>2011</year>; <volume>2</volume>(<issue>2</issue>):<fpage>80</fpage>&#x02013;<lpage>85</lpage>. <pub-id pub-id-type="pmid">21637031</pub-id></mixed-citation></ref><ref id="pone.0173802.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Gori</surname><given-names>A</given-names></name>, <name><surname>Rizzardini</surname><given-names>G</given-names></name>, <name><surname>Van't Land</surname><given-names>B</given-names></name>, <name><surname>Welling</surname><given-names>G</given-names></name>, <name><surname>Garssen</surname><given-names>J</given-names></name>, <name><surname>Clerici</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Specific prebiotics modulate gut microbiota and immune activation in HAART-na&#x000ef;ve HIV-infected adults: results of the &#x0201c;COPA&#x0201d; pilot randomized trial</article-title>. <source>NATURE</source>
<year>2011</year>; <volume>4</volume>(<issue>5</issue>): <fpage>554</fpage>&#x02013;<lpage>63</lpage>.</mixed-citation></ref><ref id="pone.0173802.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Klatt</surname><given-names>NR</given-names></name>, <name><surname>Canary</surname><given-names>LA</given-names></name>, <name><surname>Sun</surname><given-names>X</given-names></name>, <name><surname>Haddad</surname><given-names>EK</given-names></name>, <name><surname>Estes</surname><given-names>JD</given-names></name>, <name><surname>Brenchley</surname><given-names>JM</given-names></name>, <etal>et al</etal>
<article-title>Probiotic/prebiotic supplementation of antiretrovirals improves gastrointestinal immunity in SIV-infected macaques</article-title>, <source>The Journal of Clinical Investigation</source>
<year>2013</year>; <volume>123</volume>(<issue>2</issue>):<fpage>903</fpage>&#x02013;<lpage>907</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1172/JCI66227">10.1172/JCI66227</ext-link></comment>
<pub-id pub-id-type="pmid">23321668</pub-id></mixed-citation></ref><ref id="pone.0173802.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Cunningham-Rundles</surname><given-names>S</given-names></name>, <name><surname>Ahrn&#x000e9;</surname><given-names>S</given-names></name>, <name><surname>Johann-Liang</surname><given-names>R</given-names></name>, <name><surname>Grassey</surname><given-names>C</given-names></name>, <name><surname>Bengmark</surname><given-names>S</given-names></name>, <name><surname>Cervia</surname><given-names>JS</given-names></name>, <etal>et al</etal>
<article-title>Effect of probiotic bacteria on microbial host defense, growth and immune function in human immunodeficiency virus type- 1 infection</article-title>. <source>Nutrients</source>
<year>2011</year>; <volume>3</volume>(<issue>12</issue>):<fpage>1042</fpage>&#x02013;<lpage>1070</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3390/nu3121042">10.3390/nu3121042</ext-link></comment>
<pub-id pub-id-type="pmid">22292110</pub-id></mixed-citation></ref><ref id="pone.0173802.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Sandler</surname><given-names>NG</given-names></name>, <name><surname>Zhang</surname><given-names>X</given-names></name>, <name><surname>Bosch</surname><given-names>RJ</given-names></name>, <name><surname>Deeks</surname><given-names>SG</given-names></name>, <name><surname>Lederman</surname><given-names>MM</given-names></name>, <name><surname>Gandhi</surname><given-names>RT</given-names></name>
<etal>et al</etal>
<collab>AIDS Clinical Trials Group A5296 Team</collab>. <article-title>Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection</article-title>. <source>The Journal of Infectious Diseases</source>
<year>2014</year>; <volume>210</volume>(<issue>10</issue>):<fpage>1549</fpage>&#x02013;<lpage>1554</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/infdis/jiu305">10.1093/infdis/jiu305</ext-link></comment>
<pub-id pub-id-type="pmid">24864123</pub-id></mixed-citation></ref><ref id="pone.0173802.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Stiksrud</surname><given-names>B</given-names></name>, <name><surname>Nowak</surname><given-names>P</given-names></name>, <name><surname>Nwosu</surname><given-names>FC</given-names></name>, <name><surname>Hov</surname><given-names>JR</given-names></name>, <name><surname>Dyrhol-Riise</surname><given-names>AM</given-names></name>, <name><surname>Tr&#x000f8;seid</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Reduced Levels of D-dimer and Changes in Gut Microbiota Composition After Probiotic Intervention in HIV-Infected Individuals on Stable ART</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2015</year>; <volume>70</volume> (<issue>4</issue>): <fpage>329</fpage>&#x02013;<lpage>37</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/QAI.0000000000000784">10.1097/QAI.0000000000000784</ext-link></comment>
<pub-id pub-id-type="pmid">26258571</pub-id></mixed-citation></ref><ref id="pone.0173802.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Thomas</surname><given-names>S</given-names></name>, <name><surname>Przesdzing</surname><given-names>I</given-names></name>, <name><surname>Metzke</surname><given-names>D</given-names></name>, <name><surname>Schmitz</surname><given-names>J</given-names></name>, <name><surname>Radbruch</surname><given-names>A</given-names></name>, <name><surname>Baumgart</surname><given-names>DC</given-names></name>, <etal>et al</etal>
<article-title>Saccharomyces boulardii inhibits lipopolysaccharide-induced activation of human dendritic cells and T cell proliferation</article-title>. <source>Clin Exp Immunol</source>. <year>2009</year>; <volume>156</volume> (<issue>1</issue>):<fpage>78</fpage>&#x02013;<lpage>87</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1365-2249.2009.03878.x">10.1111/j.1365-2249.2009.03878.x</ext-link></comment>
<pub-id pub-id-type="pmid">19161443</pub-id></mixed-citation></ref><ref id="pone.0173802.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Im</surname><given-names>E</given-names></name>, <name><surname>Pothoulakis</surname><given-names>C</given-names></name>. <article-title>Recent advances in Saccharomyces boulardii research</article-title>. <source>Gastroenterol Clin Biol</source>. <year>2010</year>; <volume>34</volume>
<issue>Suppl 1</issue>:<fpage>S62</fpage>&#x02013;<lpage>S70</lpage>.<pub-id pub-id-type="pmid">20889007</pub-id></mixed-citation></ref><ref id="pone.0173802.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>McFarland</surname><given-names>LV</given-names></name>. <article-title>Systematic review and meta-analysis of Saccharomyces boulardii in adult patients</article-title>. <source>World. J. Gastroenterol</source>. <year>2010</year>; <volume>16</volume>(<issue>18</issue>):<fpage>2202</fpage>&#x02013;<lpage>22</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3748/wjg.v16.i18.2202">10.3748/wjg.v16.i18.2202</ext-link></comment>
<pub-id pub-id-type="pmid">20458757</pub-id></mixed-citation></ref><ref id="pone.0173802.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Canonici</surname><given-names>A</given-names></name>, <name><surname>Pellegrino</surname><given-names>E</given-names></name>, <name><surname>Siret</surname><given-names>C</given-names></name>, <name><surname>Terciolo</surname><given-names>C</given-names></name>, <name><surname>Czerucka</surname><given-names>D</given-names></name>, <name><surname>Bastonero</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Saccharomyces boulardii Improves Intestinal Epithelial Cell Restitution by Inhibiting &#x003b1;v&#x003b2;5 Integrin Activation State</article-title>. <source>PLoS ONE</source>
<year>2012</year>; <volume>7</volume>(<issue>9</issue>):p. <fpage>e45047</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0045047">10.1371/journal.pone.0045047</ext-link></comment>
<pub-id pub-id-type="pmid">23028753</pub-id></mixed-citation></ref><ref id="pone.0173802.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Pothoulakis</surname><given-names>C</given-names></name>. <article-title>Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2009</year>; <volume>30</volume>(<issue>8</issue>):<fpage>26</fpage>&#x02013;<lpage>833</lpage>.</mixed-citation></ref><ref id="pone.0173802.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Villar-Garc&#x000ed;a</surname><given-names>J</given-names></name>, <name><surname>Hern&#x000e1;ndez</surname><given-names>JJ</given-names></name>, <name><surname>G&#x000fc;erri-Fern&#x000e1;ndez</surname><given-names>R</given-names></name>, <name><surname>Gonz&#x000e1;lez</surname><given-names>A</given-names></name>, <name><surname>Lerma</surname><given-names>E</given-names></name>, <name><surname>Knobel</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Effect of probiotics (Saccharomyces boulardii) on microbial translocation and inflammation in HIV-treated patients: a double-blind, randomized, placebo-controlled trial</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2015</year>; <volume>68</volume>(<issue>3</issue>):<fpage>256</fpage>&#x02013;<lpage>63</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/QAI.0000000000000468">10.1097/QAI.0000000000000468</ext-link></comment>
<pub-id pub-id-type="pmid">25469528</pub-id></mixed-citation></ref><ref id="pone.0173802.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Klindworth</surname><given-names>A</given-names></name>, <name><surname>Pruesse</surname><given-names>E</given-names></name>, <name><surname>Schweer</surname><given-names>T</given-names></name>, <name><surname>Peplies</surname><given-names>J</given-names></name>, <name><surname>Horn</surname><given-names>M</given-names></name>, <name><surname>Gl&#x000f6;ckner</surname><given-names>FO</given-names></name>, <etal>et al</etal>
<article-title>Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studies</article-title>. <source>Nucleic Acids Res</source>. <year>2013</year>; <volume>41</volume>(<issue>1</issue>):<fpage>e1</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/nar/gks808">10.1093/nar/gks808</ext-link></comment>
<pub-id pub-id-type="pmid">22933715</pub-id></mixed-citation></ref><ref id="pone.0173802.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Caporaso</surname><given-names>JG</given-names></name>, <name><surname>Lauber</surname><given-names>CL</given-names></name>, <name><surname>Walters</surname><given-names>WA</given-names></name>, <name><surname>Gilbert</surname><given-names>JA</given-names></name>, <name><surname>Smith</surname><given-names>G</given-names></name>, <name><surname>Knight</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms</article-title>. <source>ISME J</source>. <year>2012</year>; <volume>6</volume>(<issue>8</issue>):<fpage>1621</fpage>&#x02013;<lpage>4</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ismej.2012.8">10.1038/ismej.2012.8</ext-link></comment>
<pub-id pub-id-type="pmid">22402401</pub-id></mixed-citation></ref><ref id="pone.0173802.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>Q</given-names></name>, <name><surname>Garrity</surname><given-names>GM</given-names></name>, <name><surname>Tiedje</surname><given-names>JM</given-names></name>, and <name><surname>Cole</surname><given-names>JR</given-names></name>. <article-title>Na&#x000ef;ve Bayesian Classifier for Rapid Assignment of rRNA Sequences into the New Bacterial Taxonomy</article-title>. <source>Appl Environ Microbiol</source>. <year>2007</year>; <volume>73</volume>(<issue>16</issue>):<fpage>5261</fpage>&#x02013;<lpage>5267</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/AEM.00062-07">10.1128/AEM.00062-07</ext-link></comment>
<pub-id pub-id-type="pmid">17586664</pub-id></mixed-citation></ref><ref id="pone.0173802.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Perez-Santiago</surname><given-names>J</given-names></name>, <name><surname>Gianella</surname><given-names>S</given-names></name>, <name><surname>Massanella</surname><given-names>M</given-names></name>, <name><surname>Little</surname><given-names>SJ</given-names></name>, <name><surname>Richman</surname><given-names>DD</given-names></name>, <name><surname>Smith</surname><given-names>DM</given-names></name>, <etal>et al</etal>
<article-title>Gut Lactobacillales are associated with higher CD4 and less microbial translocation during HIV infection</article-title>, <source>AIDS</source>
<year>2013</year>; (<volume>27</volume>)<issue>12</issue>:<fpage>1921</fpage>&#x02013;<lpage>1931</lpage>. <pub-id pub-id-type="pmid">24180001</pub-id></mixed-citation></ref><ref id="pone.0173802.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Swidsinski</surname><given-names>A</given-names></name>, <name><surname>Loening-Baucke</surname><given-names>V</given-names></name>, <name><surname>Kirsch</surname><given-names>S</given-names></name> and <name><surname>Doerffel</surname><given-names>Y</given-names></name>. <article-title>Functional biostructure of colonic microbiota (central fermenting area, germinal stock area and separating mucus layer) in healthy subjects and patients with diarrhea treated with Saccharomyces boulardii</article-title>. <source>Gastroenterol Clin Biol</source>. <year>2010</year>; <volume>34</volume>
<issue>Suppl 1</issue>:<fpage>S79</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">20889010</pub-id></mixed-citation></ref><ref id="pone.0173802.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Vaziri</surname><given-names>ND</given-names></name>, <name><surname>Wong</surname><given-names>J</given-names></name>, <name><surname>Pahl</surname><given-names>M</given-names></name>, <name><surname>Piceno</surname><given-names>YM</given-names></name>, <name><surname>Yuan</surname><given-names>J</given-names></name>, <name><surname>DeSantis</surname><given-names>TZ</given-names></name>, <etal>et al</etal>
<article-title>Chronic kidney disease alters intestinal microbial flora</article-title>. <source>Kidney Int</source>. <year>2013</year>
<month>2</month>;<volume>83</volume>(<issue>2</issue>):<fpage>308</fpage>&#x02013;<lpage>15</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ki.2012.345">10.1038/ki.2012.345</ext-link></comment>
<pub-id pub-id-type="pmid">22992469</pub-id></mixed-citation></ref><ref id="pone.0173802.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Ciubotaru</surname><given-names>I</given-names></name>, <name><surname>Green</surname><given-names>SJ</given-names></name>, <name><surname>Kukreja</surname><given-names>S</given-names></name>, <name><surname>Barengolts</surname><given-names>E</given-names></name>. <article-title>Significant differences in fecal microbiota are associated with various stages of glucose tolerance in African American male veterans</article-title>. <source>Transl Res</source>. <year>2015</year>
<month>11</month>;<volume>166</volume>(<issue>5</issue>):<fpage>401</fpage>&#x02013;<lpage>11</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.trsl.2015.06.015">10.1016/j.trsl.2015.06.015</ext-link></comment>
<pub-id pub-id-type="pmid">26209747</pub-id></mixed-citation></ref><ref id="pone.0173802.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Moreno-Indias</surname><given-names>I</given-names></name>, <name><surname>S&#x000e1;nchez-Alcoholado</surname><given-names>L</given-names></name>, <name><surname>Garc&#x000ed;a-Fuentes</surname><given-names>E</given-names></name>, <name><surname>Cardona</surname><given-names>F</given-names></name>, <name><surname>Queipo-Ortu&#x000f1;o</surname><given-names>MI</given-names></name>, <name><surname>Tinahones</surname><given-names>FJ</given-names></name>. <article-title>Insulin resistance is associated with specific gut microbiota in appendix samples from morbidly obese patients</article-title>. <source>Am J Transl Res</source>. <year>2016</year>
<month>12</month>
<day>15</day>;<volume>8</volume>(<issue>12</issue>):<fpage>5672</fpage>&#x02013;<lpage>5684</lpage>. <pub-id pub-id-type="pmid">28078038</pub-id></mixed-citation></ref><ref id="pone.0173802.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Ancuta</surname><given-names>P</given-names></name>, <name><surname>Kamat</surname><given-names>A</given-names></name>, <name><surname>Kunstman</surname><given-names>KJ</given-names></name>, <name><surname>Kim</surname><given-names>EY</given-names></name>, <name><surname>Autissier</surname><given-names>P</given-names></name>, <name><surname>Wurcel</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients</article-title>. <source>PLoS One</source>
<year>2008</year>; <volume>3</volume>:<fpage>e2516</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0002516">10.1371/journal.pone.0002516</ext-link></comment>
<pub-id pub-id-type="pmid">18575590</pub-id></mixed-citation></ref><ref id="pone.0173802.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Marchetti</surname><given-names>G</given-names></name>, <name><surname>Cozzi-Lepri</surname><given-names>A</given-names></name>, <name><surname>Merlini</surname><given-names>E</given-names></name>, <name><surname>Bellistri</surname><given-names>GM</given-names></name>, <name><surname>Castagna</surname><given-names>A</given-names></name>, <name><surname>Galli</surname><given-names>M</given-names></name>,<etal>et al</etal>
<article-title>Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count</article-title>. <source>AIDS</source>
<year>2011</year>; <volume>25</volume>(<issue>11</issue>):<fpage>1385</fpage>&#x02013;<lpage>94</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/QAD.0b013e3283471d10">10.1097/QAD.0b013e3283471d10</ext-link></comment>
<pub-id pub-id-type="pmid">21505312</pub-id></mixed-citation></ref><ref id="pone.0173802.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Troseid</surname><given-names>M</given-names></name>, <name><surname>Nowak</surname><given-names>P</given-names></name>, <name><surname>Nystr&#x000f6;m</surname><given-names>J</given-names></name>, <name><surname>Lindkvist</surname><given-names>A</given-names></name>, <name><surname>Abdurahman</surname><given-names>S</given-names></name> and <name><surname>S&#x000f6;nnerborg</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Elevated plasma levels of lipopolysaccharide and high mobility group box-1 protein are associated with high viral load in HIV-1 infection: reduction by 2-year antiretroviral therapy</article-title>. <source>AIDS</source>
<year>2010</year>; <volume>24</volume> (<issue>11</issue>):<fpage>1733</fpage>&#x02013;<lpage>1737</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/QAD.0b013e32833b254d">10.1097/QAD.0b013e32833b254d</ext-link></comment>
<pub-id pub-id-type="pmid">20502315</pub-id></mixed-citation></ref><ref id="pone.0173802.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Sandler</surname><given-names>NG</given-names></name>, <name><surname>Wand</surname><given-names>H</given-names></name>, <name><surname>Roque</surname><given-names>A</given-names></name>, <name><surname>Law</surname><given-names>M</given-names></name>, <name><surname>Nason</surname><given-names>MC</given-names></name>, <name><surname>Emery</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Plasma levels of soluble CD14 independently predict mortality in HIV Infection</article-title>. <source>J Infect Dis</source>. <year>2011</year>; <volume>203</volume> (<issue>6</issue>):<fpage>780</fpage>&#x02013;<lpage>790</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/infdis/jiq118">10.1093/infdis/jiq118</ext-link></comment>
<pub-id pub-id-type="pmid">21252259</pub-id></mixed-citation></ref><ref id="pone.0173802.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Dillon</surname><given-names>SM</given-names></name>, <name><surname>Lee</surname><given-names>EJ</given-names></name>, <name><surname>Kotter</surname><given-names>CV</given-names></name>, <name><surname>Robertson</surname><given-names>CE</given-names></name>, <name><surname>Frank</surname><given-names>DN</given-names></name>, <name><surname>Wilson</surname><given-names>CC</given-names></name>, <etal>et al</etal>
<article-title>An altered intestinal mucosal microbiome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia</article-title>.<source>Mucosal Immunol</source>. <year>2014</year>; <volume>7</volume>(<issue>4</issue>):<fpage>983</fpage>&#x02013;<lpage>94</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/mi.2013.116">10.1038/mi.2013.116</ext-link></comment>
<pub-id pub-id-type="pmid">24399150</pub-id></mixed-citation></ref><ref id="pone.0173802.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Marksa</surname><given-names>MA</given-names></name>, <name><surname>Rabkin</surname><given-names>CS</given-names></name>, <name><surname>Engels</surname><given-names>EA</given-names></name>, <name><surname>Rager</surname><given-names>H</given-names></name>, <name><surname>Goedert</surname><given-names>JJ</given-names></name>, <name><surname>Chaturvedi</surname><given-names>AK</given-names></name>, <etal>et al</etal>
<article-title>Markers of microbial translocation and risk of AIDS-related lymphoma</article-title>. <source>AIDS</source>
<year>2013</year>; <volume>27</volume>(<issue>3</issue>)<fpage>469</fpage>&#x02013;<lpage>474</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/QAD.0b013e32835c1333">10.1097/QAD.0b013e32835c1333</ext-link></comment>
<pub-id pub-id-type="pmid">23169327</pub-id></mixed-citation></ref><ref id="pone.0173802.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Kelesidis</surname><given-names>T</given-names></name>, <name><surname>Kendall</surname><given-names>MA</given-names></name>, <name><surname>Yang</surname><given-names>OO</given-names></name>, <name><surname>Hodis</surname><given-names>HN</given-names></name>, <name><surname>Currier</surname><given-names>JS</given-names></name>. <article-title>Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection</article-title>. <source>J Infect Dis</source>. <year>2012</year>; <volume>206</volume> (<issue>10</issue>):<fpage>1558</fpage>&#x02013;<lpage>1567</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/infdis/jis545">10.1093/infdis/jis545</ext-link></comment>
<pub-id pub-id-type="pmid">23066162</pub-id></mixed-citation></ref><ref id="pone.0173802.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Blodget</surname><given-names>E</given-names></name>, <name><surname>Shen</surname><given-names>C</given-names></name>, <name><surname>Aldrovandi</surname><given-names>G</given-names></name>, <name><surname>Gupta</surname><given-names>SK</given-names></name>, <name><surname>Stein</surname><given-names>JH</given-names></name>, <name><surname>Dub&#x000e9;</surname><given-names>MP</given-names></name>, <etal>et al</etal>
<article-title>Relationship between Microbial Translocation and Endothelial Function in HIV Infected Patients</article-title>. <source>PLoSONE</source>
<year>2012</year>; <volume>7</volume>(<issue>8</issue>): <fpage>e42624</fpage>.</mixed-citation></ref><ref id="pone.0173802.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>V&#x000e1;zquez-Castellanos</surname><given-names>JF</given-names></name>, <name><surname>Serrano-Villar</surname><given-names>S</given-names></name>, <name><surname>Latorre</surname><given-names>A</given-names></name>, <name><surname>Artacho</surname><given-names>A</given-names></name>, <name><surname>Gosalbes</surname><given-names>MJ</given-names></name>, <name><surname>Moya</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals</article-title>. <source>Mucosal Immunol</source>. <year>2015</year>; <volume>8</volume>(<issue>4</issue>):<fpage>760</fpage>&#x02013;<lpage>72</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/mi.2014.107">10.1038/mi.2014.107</ext-link></comment>
<pub-id pub-id-type="pmid">25407519</pub-id></mixed-citation></ref><ref id="pone.0173802.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Jiang</surname><given-names>W</given-names></name>, <name><surname>Lederman</surname><given-names>MM</given-names></name>, <name><surname>Hunt</surname><given-names>P</given-names></name>, <name><surname>Deeks</surname><given-names>SG</given-names></name>, <name><surname>Douek</surname><given-names>DC</given-names></name>, <name><surname>Brenchley</surname><given-names>JM</given-names></name>, <etal>et al</etal>
<article-title>Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection</article-title>. <source>J Infect Dis</source>. <year>2009</year>; <volume>199</volume> (<issue>8</issue>): <fpage>1177</fpage>&#x02013;<lpage>1185</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1086/597476">10.1086/597476</ext-link></comment>
<pub-id pub-id-type="pmid">19265479</pub-id></mixed-citation></ref><ref id="pone.0173802.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Piconi</surname><given-names>S</given-names></name>, <name><surname>Trabattoni</surname><given-names>D</given-names></name>, <name><surname>Gori</surname><given-names>A</given-names></name>, <name><surname>Parisotto</surname><given-names>S</given-names></name>, <name><surname>Capetti</surname><given-names>A</given-names></name>, <name><surname>Rizzardini</surname><given-names>G</given-names></name>, <name><surname>Clerici</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy</article-title>. <source>AIDS</source>
<year>2010</year>; <volume>24</volume> (<issue>13</issue>):<fpage>1991</fpage>&#x02013;<lpage>2000</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/QAD.0b013e32833c93ce">10.1097/QAD.0b013e32833c93ce</ext-link></comment>
<pub-id pub-id-type="pmid">20651586</pub-id></mixed-citation></ref><ref id="pone.0173802.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Klatt</surname><given-names>NR</given-names></name>, <name><surname>Funderburg</surname><given-names>NT</given-names></name> and <name><surname>Brenchley</surname><given-names>JM</given-names></name>. <article-title>Microbial translocation, immune activation and HIV disease</article-title>. <source>Trends Microbiol</source>. <year>2013</year>; <volume>21</volume>(<issue>1</issue>): <fpage>6</fpage>&#x02013;<lpage>13</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.tim.2012.09.001">10.1016/j.tim.2012.09.001</ext-link></comment>
<pub-id pub-id-type="pmid">23062765</pub-id></mixed-citation></ref><ref id="pone.0173802.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Klase</surname><given-names>Z</given-names></name>, <name><surname>Ortiz</surname><given-names>A</given-names></name>, <name><surname>Deleage</surname><given-names>C</given-names></name>, <name><surname>Mudd</surname><given-names>JC</given-names></name>, <name><surname>Qui&#x000f1;ones</surname><given-names>M</given-names></name>, <name><surname>Schwartzman</surname><given-names>E</given-names></name>, <etal>et al</etal>
<article-title>Dysbiotic bacteria translocate in progressive SIV infection</article-title>. <source>Mucosal Immunol</source>. <month>9</month>
<year>2015</year>;<volume>8</volume>(<issue>5</issue>):<fpage>1009</fpage>&#x02013;<lpage>1020</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/mi.2014.128">10.1038/mi.2014.128</ext-link></comment>
<pub-id pub-id-type="pmid">25586559</pub-id></mixed-citation></ref><ref id="pone.0173802.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Williams</surname><given-names>B</given-names></name>, <name><surname>Mirmonsef</surname><given-names>P</given-names></name>, <name><surname>Boucher</surname><given-names>CA</given-names></name>, <name><surname>Bushman</surname><given-names>F</given-names></name>, <name><surname>Carrington-Lawrence</surname><given-names>S</given-names></name>, <name><surname>Collman</surname><given-names>RG</given-names></name>
<etal>et al</etal>
<article-title>A Summary of The First HIV Microbiome Workshop 2015</article-title>. <source>AIDS Res Hum Retroviruses</source>. <year>2016</year>
<season>Oct-Nov</season>;<volume>32</volume>(<issue>10&#x02013;11</issue>):<fpage>935</fpage>&#x02013;<lpage>941</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1089/AID.2016.0034">10.1089/AID.2016.0034</ext-link></comment>
<pub-id pub-id-type="pmid">27267576</pub-id></mixed-citation></ref><ref id="pone.0173802.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Swidsinski</surname><given-names>A</given-names></name>, <name><surname>Loening-Baucke</surname><given-names>V</given-names></name>, <name><surname>Schulz</surname><given-names>S</given-names></name>, <name><surname>Manowsky</surname><given-names>J</given-names></name>, <name><surname>Verstraelen</surname><given-names>H</given-names></name>, <name><surname>Swidsinski</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Functional anatomy of the colonic bioreactor: Impact of antibiotics and Saccharomyces boulardii on bacterial composition in human fecal cylinders</article-title>. <source>Syst Appl Microbiol</source>. <year>2016</year>
<month>2</month>;<volume>39</volume>(<issue>1</issue>):<fpage>67</fpage>&#x02013;<lpage>75</lpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.syapm.2015.11.002">10.1016/j.syapm.2015.11.002</ext-link></comment>
<pub-id pub-id-type="pmid">26723852</pub-id></mixed-citation></ref></ref-list></back></article>